Next-Generation Antifungals Powered by Genomic Intelligence

— The Problem —

Fungal pathogens threaten both human health and global food security. Resistance to existing fungicides and antifungal drugs is accelerating, while the development of new modes of action has stagnated.

With limited therapeutic options and growing resistance across agriculture and medicine, the world faces a critical erosion of efficacy in current treatments. GenoMyco was founded to change this trajectory.

Food security threat

$220B+

Annual global crop losses from fungal disease

Healthcare threat

$48B+

Annual direct cost of fungal infections in human

— Our Strategy —

Turning Constraint into Advantage

The biological similarity between fungi and their hosts has fundamentally limited antifungal innovation. Specificity remains the central challenge and the reason new mechanisms of action are rare.

GenoMyco uses genomics to convert conserved biology into fungal-selective targets. Through high-resolution genomic and structural analysis, we identify fungal-specific features within conserved pathways and use them to develop novel and precise antifungal.

— Market Context —

Creating Strategic Advantage in Antifungal Innovation

Antifungal resistance is reshaping a $37B global market. The World Health Organization (WHO) classifies fungal resistance as a critical global threat, a warning that extends to agriculture, where resistance is eroding the lifespan and value of major agrochemical portfolios. As a result, companies are shifting from generic competition toward proprietary, IP-backed differentiation. Durable control therefore requires truly novel, defensible mechanisms of action (MoA).

GenoMyco develops novel antifungal MoA based on fungal genomics and protects them through target-driven IP, including chemistry designed for fungal-selective structural elements. By focusing on these structures, we enable partners to open new chemical classes and extend the economic life of existing portfolios while reducing early-stage uncertainty through mechanism-driven discovery.

We provide agrochemical and pharmaceutical partners with patented MoA that accelerate pipeline development, shorten discovery timelines, strengthen portfolio durability, and support capital-efficient innovation in a highly regulated market.

— Team & Vision —

Our Team

GenoMyco is powered by a multidisciplinary team of experts from complementary scientific fields. We believe that the people behind the technology are the true catalysts for innovation. By integrating advanced technology with experienced scientific and entrepreneurial leadership, we translate discovery into real-world applications. This synergy allows us to turn vision into significant impact.